United Therapeutics Corp. Stock Price, News & Analysis

United Therapeutics Corporation (Nasdaq: UTHR) will present an update on its business at the Credit Suisse 30th Annual Healthcare Conference on November 8, 2021, from 8:50 a.m. to 9:30 a.m. EST. Michael Benkowitz, President and COO, will lead the discussion. The session will be available via live webcast on the company's website, with an archived version accessible 24 hours post-event for 90 days. United Therapeutics aims to cure pulmonary arterial hypertension and is notable for being the first publicly-traded company structured as a public benefit corporation.

Volumetric, a Houston-based biofabrication start-up, has been acquired by 3D Systems (NYSE: DDD) for an initial payment of $45 million, with potential milestone earnouts up to $355 million. The acquisition aims to advance bioprinting technology for human organ replacement, enhancing regenerative medicine capabilities. Volumetric's 20,000 sq. ft. facility will be established in Houston's East End Maker Hub. This deal strengthens 3D Systems' partnership with United Therapeutics Corporation (NASDAQ: UTHR) for organ therapy development.

United Therapeutics Corporation (Nasdaq: UTHR) has announced it will release its third quarter 2021 financial results on November 3, 2021, before the market opens. A public webcast will take place on the same day at 9:00 a.m. Eastern Time, accessible via the company's website. The company focuses on finding a cure for pulmonary arterial hypertension and has received FDA approval for five medications. United Therapeutics operates as a public benefit corporation, aiming to enhance shareholder value while promoting sustainability and healthcare advancements.

On October 21, 2021, United Therapeutics (Nasdaq: UTHR) presented significant clinical data at CHEST 2021 regarding pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The highlight was the new pharmacokinetic data from the BREEZE study of Tyvaso DPI, which showed comparable systemic exposure to existing Tyvaso treatments with reduced variability. The data indicate successful transitions from Tyvaso to Tyvaso DPI, enhancing patient outcomes, such as improved walking distance and overall satisfaction.

United Therapeutics Corporation (Nasdaq: UTHR) announced a setback in the FDA review of its new drug application for Tyvaso DPI™ for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). On October 15, 2021, the FDA issued a complete response letter citing a single deficiency at a third-party testing facility, delaying approval. The company aims to resolve this issue and anticipates resubmission by summer 2022.

United Therapeutics Corporation (Nasdaq: UTHR) announced the presentation of new data on pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) at the CHEST 2021 meeting, scheduled for October 17-20, 2021. The company will showcase 10 abstracts, including pharmacokinetic data from the BREEZE study of Tyvaso DPI™. This study involved 51 PAH patients and aimed to assess the safety and tolerability of Tyvaso DPI. Highlights also include real-world analyses of Orenitram and implications for patient care.

On September 30, 2021, United Therapeutics Corporation (Nasdaq: UTHR) announced its conversion to a public benefit corporation (PBC) following shareholder approval. This marks the first conversion of a public biotech company to a PBC, aligning its corporate structure with its mission to improve patient health, enhance employee engagement, and address sustainability. The company aims to advance the development of novel pharmaceuticals and organ transplant technologies while ensuring strong shareholder returns. Stakeholder support for this initiative underlines its commitment to responsible corporate practices.

United Therapeutics Corporation (Nasdaq: UTHR) released its second annual Corporate Responsibility Report highlighting its commitment to environmental, social, and governance (ESG) priorities for 2020. The report utilizes frameworks from Global Reporting Initiative (GRI), Sustainability Accounting Standards Board (SASB), and Task Force on Climate-Related Financial Disclosures (TCFD). Dewey Steadman stated that the report demonstrates progress in transparency and reaffirms the company's leadership in ESG management. More details are available at corporateresponsibility.unither.com.

United Therapeutics Corporation (Nasdaq: UTHR) showcased the BREEZE study results for Tyvaso DPI™ at the European Respiratory Society Congress 2021. This next-generation inhalation solution for pulmonary arterial hypertension (PAH) demonstrated significant safety and tolerability, with 96% completion rate in a three-week trial. Key findings included an 11.5-meter increase in six-minute walk distance and enhanced patient satisfaction with the device. The FDA is expected to review Tyvaso DPI's NDA in October 2021, which could enhance therapeutic accessibility for PAH patients.